Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Licaminlimab in Dry Eye Disease (RELIEF)
NCT05896670Phase 2Completed
- Sponsor
- Oculis
- Start
- Nov 2023
- Primary completion
- Mar 2024
- Modality
- scFv Fragments
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in dry eye disease (DED) comparing Licaminlimab with Vehicle (2 arms). Primary endpoint: Efficacy of licaminlimab in subjects with signs of dry eye disease at Day 43. Started Nov 2023; status: completed.
02
Drugs
licaminlimab
03
Conditions
dry eye disease (DED)
Beyond the preview
Go deeper on NCT05896670.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05896670.